Activation of the MET protooncogene through a rearrangement mechanism was originally observed in a human osteogenic sarcoma cell line (HOS) treated in vitro with the chemical carcinogen, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (1, 2) . The process involved chromosomal DNA rearrangement resulting in the fusion of a TPR (translocated promoter region) locus on chromosome 1 to the 5' region of sequences derived from the MET locus on chromosome 7 (3, 4) . The MET protooncogene is predominantly expressed in human fibroblast and epithelial cell lines as a 9.0-kilobase (kb) transcript, with additional expression of MET-related RNAs of 7.0 and 6.0 kb (4) . The activated TPR-MET oncogene expresses a 5.0-kb hybrid RNA encoding a 65-kDa fusion protein (3, 4) .
The MET protooncogene is a member of the tyrosine kinase growth-factor gene family, encoding a 190-kDa transmembrane glycoprotein as its major product. The mechanism of its activation by gene rearrangement is similar to that ofthe human BCR-ABL gene in the Philadelphia chromosome translocation occurring in chronic myeloid leukemic cells (5) (6) (7) (8) and also to the activation of TRK oncogene isolated from a human colon carcinoma, in which 5' sequences derived from a nonmuscle tropomyosin were fused to a truncated receptor protein-tyrosine kinase (9) . The activated TPR-METgene was isolated from a late (> 150) passage of an MNNG-treated HOS cell line (MNNG-HOS) by molecular cloning of the transforming sequence (2) , and its presence in well-established transformed cell lines has been detected by nucleic acid hybridization analysis. Such procedures are time consuming and require a large number of cells for DNA and RNA isolations. MET protooncogene activation through rearrangement has been observed only in MNNG-transformed human cells, and no information has been available concerning the possible occurrence of this rearrangement in human tumors. We therefore sought to develop a method for detection of the TPR-MET rearrangement that would have adequate sensitivity to allow detection even when it is present in very few cells. Saiki et al. (10) have described a sensitive method of gene amplification, polymerase chain reaction (PCR), which has been applied widely for detecting single base pair mutations (11) (12) (13) as well as DNA rearrangements (14, 15) . Recently, use of the PCR method has been extended to include RNA as the starting template and has been used for the detection of the BCR-ABL rearrangement (16) , for cloning of HLA-DQ sequences (17) , and also for determining the mechanism for tissue-specific processing of an apolipoprotein mRNA (18) . Here, we describe a rapid and highly sensitive method of transcript amplification for detection of TPR-MET gene rearrangement in human cells. Using this method, we have screened cell lines derived from several types of human tumors, and results indicate that this rearrangement may occur and be expressed at low frequencies in malignancies of several nonhematopoietic tissues. 19) , and 3-methylcholanthrene-treated HOS (3MC-312H HOS) (3MC, 10 .0 ug/ml) have been described (19) (20) (21) (22) . The HOS cells and derivatives were grown in Eagle's minimal essential medium containing 10% fetal bovine serum and 1% penicillin/streptomycin at 370C. The remaining cells were purchased from American Type Culture Collection (ATCC) and were grown according to the specified protocols.
MATERIALS AND METHODS
Abbreviations: PCR, polymerase chain reaction; MNNG, Nmethyl-N'-nitro-N-nitrosoguanidine; DMBA, dimethylbenz[a]anthracene; 3MC, 3-methylcholanthrene.
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Total RNA was isolated from confluent (108-109) cells by the acid/guanidinium/phenol/chloroform extraction method (23) . Poly(A)+ RNA was selected on an oligo(dT)-cellulose column as described by Aviv and Leder (24) . About 1.0 Ag of poly(A)+ RNA was used to monitor the sensitivity of the PCR assay.
Oligonucleotides were synthesized on a model 3A DNA synthesizer (Applied Biosystems) and purified with oligonucleotide purification cartridges (Applied Biosystems) as described by the manufacturer. Two sets of oligonucleotide primers were used, having the following sequences (25) (Fig. 1) . Primers Ta and Mb were also used as internal probes for detecting the rearrangement.
First and second strand cDNA were initially synthesized from poly(A)+ RNA isolated from the parental cell line HOS or from its derivative, MNNG-HOS cell line, in a one-tube reaction recently described by Gubler (26) . The cDNA was subjected to PCR analysis (see below) using the primers Ta and Mb. DNA amplification was carried out with Thermus aquaticus DNA polymerase (Taq polymerase) and a thermal DNA cycler (Perkin-Elmer/Cetus). The reaction mixture contained 100 ng of cDNA, 200 ,LM dNTPs, and 1.0 ,uM each primer in 100 ,ul of PCR buffer (50 mM Tris-HCI/50 mM KCI/2.5 mM MgCl2/100 ,g of bovine serum albumin per ml, pH 8.4). The reaction mixture was incubated for 7 min at 94°C to denature any contaminating proteins present. One unit of Taq polymerase was added to the reaction mixture and overlaid with a drop of mineral oil to prevent evaporation. The samples were denatured at 94°C for 1 min, and the primers were allowed to anneal at 37°C for 2 min and then extended at 72°C for 3 min. Each cycle was repeated 40 times and, at the end of the last cycle, the products were extended at 72°C for 7 min to allow annealing of the products and they were stored at 0°C.
Direct DNA sequencing was carried out as follows. The amplified products (using Ta and Mb) were extracted with chloroform (to remove mineral oil), precipitated with ethanol, and resuspended in TE (10 mM Tris HCI/1 mM EDTA, pH 7.5) buffer. An aliquot was run on a native 10% polyacrylamide gel and visualized by ethidium bromide staining. The 70-bp DNA fragment was cut out of the gel, eluted tpr (Chromosome I ) overnight in lx TBE (50 mM Tris HCl/50 mM boric acid/20 mM Na2EDTA), ethanol precipitated, and resuspended in TE buffer. About 0.5-1.0 ,ug of DNA was used for direct DNA sequencing. Primer Mb was end-labeled using [y-32P]ATP (New England Nuclear; 6000 Ci/mmol; 1 Ci = 37 GBq) and T4 polynucleotide kinase (BRL). About 8.0 pmol of the labeled primer was used to sequence the 70-bp amplified DNA on a 10% polyacrylamide/7 M urea gel using Sequenase enzyme and a DNA sequencing kit (United States Biochemical) (13) .
In For detection of PCR products by solution hybridization, a sample containing 10% of PCR-amplified RNA products was hybridized in solution to 32P-end-labeled internal probes, Ta and/or Mb, after adjusting the salt concentration to 300 mM. The hybridization was carried out for 1-2 hr at 56°C, after which a sample containing =6% of the products was separated on a native 10% polyacrylamide gel, which was then exposed to Kodak x-ray film with an intensifier screen.
RESULTS
Poly(A)+ RNA isolated from HOS and MNNG-HOS cells was reverse transcribed and subjected to PCR analysis using the primers Ta from the TPR region and Mb from the MET region. Fig. 2A shows the 70-bp amplified product from MNNG-HOS RNA. The amplified DNA was purified from the gel and sequenced by using end-labeled oligonucleotide Mb as primer. The DNA sequences of Mb were complementary to that of the 3' portion of TPR-MET cDNA. Fig. 2B shows the sequence of the amplified DNA derived from the upstream portion of the MET gene. The sequence shown is complementary to the TPR sequence, thus confirming the presence of the TPR-MET rearrangement in the MNNG-HOS cell line.
Cells from several HOS and MNNG-HOS cell lines were analyzed by the modified PCR method for transcript amplification, using primers T2 and M2, after which the amplified products were probed with internal primers, Ta and/or Mb, by solution hybridization (Fig. 3) . As shown in Fig. 1 , the primers T2 and M2 amplified a 205-bp DNA region of the TPR-MET hybrid cDNA, and To determine the sensitivity of this method, 1 ,ug of poly(A)+ RNA from MNNG-HOS cell line was serially diluted with HOS poly(A)+ RNA and analyzed by the modified PCR method. End-labeled Mb primer was used to detect the rearrangement. Fig. 4 tion) were screened, with the results summarized in Fig. 6 and previously been mapped to the region 7q21-7q31 (27) . The specific chromosome containing activated MET could not be identified, but three marker chromosomes (ml, m2, and m4) were suggested as possible locations. m4 was present in only MNNG-HOS cells, but the parental line HOS also contained ml and m2. Ifthe rearrangement were present on one ofthese chromosomes in the parental HOS cells, treatment with MNNG might have selected for it through mechanisms that may or may not have involved further DNA damage of the several types known to be produced by MNNG (point mutations, sister chromosome exchanges, and chromosomal aberrations). In this context, it should also be noted that DMBA-HOS cells showed enhanced expression of TPR-MET specific RNA by nearly 10-fold compared to the parental HOS line. Furthermore, HOS 6374 cell line, a clone of HOS TE-85 that had been cultured for nearly 62 passages, did not express detectable levels of TPR-MET RNA. It is possible that in the absence of any selection pressure, the few cells expressing the hybrid RNA were eventually lost. These data suggest that selection (of rearranged cells) may contribute to TPR-MET oncogenic transformation.
Characteristic translocation-specific rearrangements occur in several types of malignancy of the hematopoietic system, such as the BCR-ABL gene fusion in chronic myeloid leukemia, and the BCL2-JH and BCLI-JH in B-cell lymphomas (5) (6) (7) (8) (28) (29) (30) (31) . Similarity has been noted in the structure of the activated METgene with those of the activated TRK and ABL genes in which domains at the 3' ends of the genes encode a tyrosine kinase, while transcriptional promotion is contributed by distinct DNA domains comprising the 5' ends of the activated genes, suggesting that these genes encode aberrant tyrosine kinases that do not respond to normal cellular control mechanisms (3) . The frequent occurrence of nonrandom deletions ofthe long arm of chromosome 7, the locus ofthe MET oncogene, in leukemic cells of patients with acute nonlymphocytic leukemia (ANLL) has also been noted (32, 33).
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Exposure to environmental carcinogens and mutagenic chemotherapeutic agents has been associated with development of ANLL (32, 34) , an observation of interest in connection with the activation of MET in HOS cells by MNNG (27) .
In MNNG-HOS cells, the coding sequences of TPR and MET regions are interrupted by a large intron region. Our initial attempts to PCR amplify genomic DNA sequences spanning the breakpoint were not successful, largely due to nonspecific amplifications from the noncoding regions. However, amplification of cDNA gave the expected DNA fragment specific for the TPR-MET rearrangement. Dean et al. (35) have reported the TPR-MET oncogenic breakpoint to occur in the intervening sequence at the end of a stretch of 21 A residues following a TPR Alu sequence and within 3 A residues in the MET protooncogene locus of the MNNG-HOS cell line. Stretches of A residues are distributed throughout the 5' noncoding region of the MET locus. The transcript PCR method used in these studies would amplify the rearrangement irrespective of the genomic location of the breakpoint, which may occur anywhere in the intron region between TPR and MET loci.
PCR amplification has proven to be a powerful tool for the detection of neoplastic cells containing genetic alterations in the presence of a large excess of their normal counterparts (15, 16) . The technique described here was highly sensitive with respect to its ability to detect the sequence alterations of Amplification and overexpression of MET has been described in a human gastric tumor cell line (GTL-16), suggesting the possible involvement of this oncogene in gastric tumors (36) . This is the only report to date of a functional alteration of MET in a human tumor cell line. Results obtained from our analysis of 14 human tumor cell lines of different cell lineages indicate that the TPR-MET specific rearrangement may occur at very low frequencies in nonhematopoietic tumor cells of several types. It would be of interest to determine whether these TPR-MET positive cell lines could be induced by MNNG or other chemical carcinogens to overexpress the rearranged RNA. The method developed for these studies will be useful in screening larger numbers of human tumors for the occurrence of MET activation and also for the determination of the possible importance of environmental mutagens and carcinogens in MET activation through the induction or expression of this rearrangement.
